Business Context and Reporting Period
This Form 8-K Current Report was filed by Phio Pharmaceuticals Corp. on December 21, 2018, covering events occurring on December 19, 2018. The filing addresses a modification to the compensatory arrangements of the Company's Chief Executive Officer, Geert Cauwenbergh.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting a specific executive compensation agreement amendment.
Material Changes
The Board of Directors approved an extension of the CEO's prior election to receive 50% of his base salary and cash bonuses in the form of unvested restricted stock units (RSUs). The material changes include:
- Extension Period: The election period was extended from the original end date of December 31, 2018, to February 28, 2019.
- Vesting Schedule: The vesting date for all RSUs granted under this election (including those from the initial period) was moved from January 1, 2019, to March 1, 2019.
- Conditions: Vesting remains subject to the CEO's continued employment with the Company.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding the Company's business strategy or market conditions. No specific risks or contingencies are disclosed in this report other than the standard condition that the RSU vesting is contingent upon the CEO's continued employment.
Investor Verification Checklist
- Verify the full text of the "Amendment No. 1 to Cauwenbergh Non-Plan Stock Compensation Election Agreement" filed as Exhibit 10.1.
- Confirm the total number of RSUs granted during the initial period (September 15, 2018, to December 31, 2018) and the new vesting date of March 1, 2019.
- Review the September 4, 2018, Form 8-K to understand the original Terms and Conditions of the Non-Plan Stock Compensation Election.